These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 24401270)

  • 1. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.
    Gutierrez A; Pan L; Groen RW; Baleydier F; Kentsis A; Marineau J; Grebliunaite R; Kozakewich E; Reed C; Pflumio F; Poglio S; Uzan B; Clemons P; VerPlank L; An F; Burbank J; Norton S; Tolliday N; Steen H; Weng AP; Yuan H; Bradner JE; Mitsiades C; Look AT; Aster JC
    J Clin Invest; 2014 Feb; 124(2):644-55. PubMed ID: 24401270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of PP2A by perphenazine induces apoptosis in T-ALL.
    Cancer Discov; 2014 Mar; 4(3):OF14. PubMed ID: 24596208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of perphenazine on canine lymphoma.
    Tsuji S; Yabe R; Usui T; Mizuno T; Ohama T; Sato K
    J Vet Med Sci; 2016 Sep; 78(8):1293-8. PubMed ID: 27150024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracted: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
    Morita K; He S; Nowak RP; Wang J; Zimmerman MW; Fu C; Durbin AD; Martel MW; Prutsch N; Gray NS; Fischer ES; Look AT
    Cell; 2020 Apr; 181(3):702-715.e20. PubMed ID: 32315619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency.
    Blackburn JS; Liu S; Raiser DM; Martinez SA; Feng H; Meeker ND; Gentry J; Neuberg D; Look AT; Ramaswamy S; Bernards A; Trede NS; Langenau DM
    Leukemia; 2012 Sep; 26(9):2069-78. PubMed ID: 22538478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
    Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
    Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
    Liu L; Huang Z; Chen J; Wang J; Wang S
    J Exp Clin Cancer Res; 2018 Jul; 37(1):142. PubMed ID: 29986744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
    Garcia EG; Veloso A; Oliveira ML; Allen JR; Loontiens S; Brunson D; Do D; Yan C; Morris R; Iyer S; Garcia SP; Iftimia N; Van Loocke W; Matthijssens F; McCarthy K; Barata JT; Speleman F; Taghon T; Gutierrez A; Van Vlierberghe P; Haas W; Blackburn JS; Langenau DM
    Leukemia; 2021 Mar; 35(3):679-690. PubMed ID: 32606318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
    Lin S; Tian L; Shen H; Gu Y; Li JL; Chen Z; Sun X; You MJ; Wu L
    Oncogene; 2013 Oct; 32(40):4845-53. PubMed ID: 23108395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
    Minuzzo S; Agnusdei V; Pusceddu I; Pinazza M; Moserle L; Masiero M; Rossi E; Crescenzi M; Hoey T; Ponzoni M; Amadori A; Indraccolo S
    Carcinogenesis; 2015 Jan; 36(1):115-21. PubMed ID: 25355291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A has an essential role in promoting thymocyte survival during selection.
    Zheng M; Li D; Zhao Z; Shytikov D; Xu Q; Jin X; Liang J; Lou J; Wu S; Wang L; Hu H; Zhou Y; Gao X; Lu L
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12422-12427. PubMed ID: 31152132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.
    Suo S; Zhao D; Li F; Zhang Y; Rodriguez-Rodriguez S; Nguyen LXT; Ghoda L; Carlesso N; Marcucci G; Zhang B; Jin J
    Blood; 2024 Sep; 144(12):1343-1347. PubMed ID: 38968151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch ankyrin repeat domain variation influences leukemogenesis and Myc transactivation.
    Aster JC; Bodnar N; Xu L; Karnell F; Milholland JM; Maillard I; Histen G; Nam Y; Blacklow SC; Pear WS
    PLoS One; 2011; 6(10):e25645. PubMed ID: 22022427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
    Masiero M; Minuzzo S; Pusceddu I; Moserle L; Persano L; Agnusdei V; Tosello V; Basso G; Amadori A; Indraccolo S
    Leukemia; 2011 Apr; 25(4):588-98. PubMed ID: 21263446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.